Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
NCT ID NCT07726160
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize and attack a protein called BCMA found on myeloma cells. The study aims to evaluate the safety of different doses and look for early signs that the treatment can reduce or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental CAR-T cell therapy called KIV-318 that targets BCMA on myeloma cells
- What this could lead to
- If successful, this could point toward a new treatment option for multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small phase 1 trial focused on safety, so it is unknown whether KIV-318 will work or cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China, 300041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••